| std_act_id |
standard_type |
definition |
standard_units |
normal_range_min |
normal_range_max |
| 1 |
CC50 |
Concentration required for 50% cytotoxicity |
nM |
1 |
10000000 |
| 2 |
EC50 |
Effective concentration for 50% activity |
nM |
0.01 |
100000 |
| 3 |
GI50 |
Concentration required for 50% growth inhibition |
nM |
1 |
10000000 |
| 4 |
IC50 |
Concentration required for 50% inhibition |
nM |
0.01 |
100000 |
| 5 |
Ki |
Inhibition constant |
nM |
0.01 |
100000 |
| 6 |
Solubility |
Solubility |
nM |
100 |
1000000000 |
| 7 |
Solubility |
Solubility |
ug.mL-1 |
0.05 |
50000 |
| 8 |
T1/2 |
Half-life |
hr |
0.001 |
10000 |
| 9 |
CL |
Clearance |
mL.min-1.g-1 |
0 |
10000 |
| 10 |
CL |
Clearance |
mL.min-1.kg-1 |
0 |
10000 |
| 11 |
CL_renal |
Renal clearance |
mL.min-1.kg-1 |
0 |
10000 |
| 12 |
CL/F |
Clearance/Bioavailability |
mL.min-1.kg-1 |
0 |
10000 |
| 13 |
CLogD |
Calculated Log(Distribution Coefficient) |
- |
-10 |
15 |
| 14 |
CLogD7.4 |
Calculated Log(Distribution Coefficient) at pH7.4 |
- |
-10 |
15 |
| 15 |
CLogP |
Calculated Log(Partition Coefficient) |
- |
-10 |
15 |
| 16 |
F |
Bioavailability |
% |
0 |
150 |
| 17 |
IC95 |
Concentration required for 95% inhibition |
nM |
0.01 |
100000 |
| 18 |
IFI |
Inhibition Frequency (promiscuity) Index |
% |
0 |
100 |
| 19 |
Inhibition |
Inhibition |
% |
-10 |
150 |
| 20 |
LogP |
Log(Partition Coefficient) |
- |
-10 |
15 |
| 21 |
LogPapp |
Log(Apparent permeability) |
- |
-10 |
15 |
| 22 |
Tmax |
Time for maximum concentration |
hr |
0.01 |
1000 |
| 23 |
Vd |
Volume of Distribution |
L.kg-1 |
0.01 |
1000 |
| 24 |
Vdss |
Steady State Volume of Distribution |
L.kg-1 |
0.01 |
1000 |
| 25 |
XC50 |
Concentration required for 50% effect |
nM |
0.01 |
100000 |
| 26 |
Vd/F |
Volume of distribution after non-intravenous administration |
L.kg-1 |
0.01 |
1000 |
| 27 |
Cmax |
Maximum concentration |
ug.mL-1 |
0.0005 |
5000 |
| 28 |
Cmax |
Maximum concentration |
nM |
1 |
10000000 |
| 29 |
IC50 |
Concentration required for 50% inhibition |
ug.mL-1 |
0.000005 |
50 |
| 30 |
MRT |
Mean residence time |
hr |
0.01 |
1000 |
| 31 |
IC90 |
Concentration required for 90% inhibition |
nM |
0.01 |
100000 |
| 32 |
IC90 |
Concentration required for 90% inhibition |
ug.mL-1 |
0.000005 |
50 |
| 33 |
MCC |
Minimum cytotoxic concentration |
nM |
1 |
10000000 |
| 34 |
MCC |
Minimum cytotoxic concentration |
ug.mL-1 |
0.0005 |
5000 |
| 35 |
MIC |
Minimum inhibitory concentration |
nM |
1 |
10000000 |
| 36 |
MIC |
Minimum inhibitory concentration |
ug.mL-1 |
0.0005 |
5000 |
| 37 |
Kd |
Dissociation constant |
nM |
0.01 |
100000 |
| 38 |
Vdss/F |
Volume of distribution at steady state after non-intravenous administration |
L.kg-1 |
0.01 |
1000 |
| 39 |
CC50 |
Concentration required for 50% cytotoxicity |
ug.mL-1 |
0.0005 |
5000 |
| 40 |
EC50 |
Effective concentration for 50% activity |
ug.mL-1 |
0.000005 |
50 |
| 41 |
GI50 |
Concentration required for 50% growth inhibition |
ug.mL-1 |
0.0005 |
5000 |
| 42 |
IC99 |
Concentration required for 99% inhibition |
nM |
0.01 |
100000 |
| 43 |
IC99 |
Concentration required for 99% inhibition |
ug.mL-1 |
0.000005 |
50 |
| 44 |
LC50 |
Concentration required for 50% lethality |
nM |
1 |
10000000 |
| 45 |
LC50 |
Concentration required for 50% lethality |
ug.mL-1 |
0.0005 |
5000 |
| 46 |
TGI |
Concentration required for total growth inhibition |
nM |
1 |
10000000 |
| 47 |
TGI |
Concentration required for total growth inhibition |
ug.mL-1 |
0.0005 |
5000 |
| 48 |
LD50 |
Dose required for 50% lethality |
mg.kg-1 |
0.0005 |
5000 |
| 49 |
LD50 |
Dose required for 50% lethality |
umol.kg-1 |
0.001 |
10000 |
| 50 |
Km |
Michaelis constant |
nM |
10 |
100000000 |
| 51 |
Potency |
Concentration or dose required to elicit a specific response |
nM |
1 |
10000000 |
| 52 |
AC50 |
Concentration required for 50% activity |
nM |
0.01 |
100000 |
| 53 |
ED50 |
Effective dose for 50% activity |
mg.kg-1 |
0.0005 |
500 |
| 54 |
IZ |
Zone of inhibition |
mm |
0 |
50 |
| 55 |
MIC50 |
Minimum inhibitory concentration in 50% of population |
nM |
1 |
10000000 |
| 56 |
MIC80 |
Minimum inhibitory concentration in 80% of population |
nM |
1 |
10000000 |
| 57 |
MIC90 |
Minimum inhibitory concentration in 90% of population |
nM |
1 |
10000000 |
| 58 |
MIC50 |
Minimum inhibitory concentration in 50% of population |
ug.mL-1 |
0.0005 |
5000 |
| 59 |
MIC80 |
Minimum inhibitory concentration in 80% of population |
ug.mL-1 |
0.0005 |
5000 |
| 60 |
MIC90 |
Minimum inhibitory concentration in 90% of population |
ug.mL-1 |
0.0005 |
5000 |
| 61 |
MIC70 |
Minimum inhibitory concentration in 70% of population |
ug.mL-1 |
0.0005 |
5000 |
| 62 |
ID50 |
Dose required for 50% inhibition |
mg.kg-1 |
0.0005 |
500 |
| 63 |
ID50 |
Dose required for 50% inhibition |
umol.kg-1 |
0.001 |
1000 |
| 64 |
ED50 |
Effective dose for 50% activity |
umol.kg-1 |
0.001 |
1000 |
| 65 |
k_obs |
Observed rate constant |
s-1 |
0.000001 |
100000 |
| 66 |
k_on |
Association rate constant |
M-1.s-1 |
1 |
10000000 |
| 67 |
k_off |
Dissociation rate constant |
s-1 |
0.000001 |
1000 |
| 68 |
CK |
A measurement of the total creatine kinase in a biological specimen. |
U.L-1 |
|
|
| 69 |
PT |
A blood clotting measurement that evaluates the extrinsic pathway of coagulation. |
s |
|
|
| 70 |
ALB |
A measurement of the albumin protein in a biological specimen. |
ug.mL-1 |
|
|
| 71 |
ALP |
A measurement of the alkaline phosphatase in a biological specimen. |
U.L-1 |
|
|
| 72 |
ALP |
A measurement of the alkaline phosphatase in a biological specimen. |
IU.L-1 |
|
|
| 73 |
ALT |
A measurement of the alanine aminotransferase in a biological specimen. |
U.L-1 |
|
|
| 74 |
ALT |
A measurement of the alanine aminotransferase in a biological specimen. |
IU.L-1 |
|
|
| 75 |
AST |
A measurement of the aspartate aminotransferase in a biological specimen. |
U.L-1 |
|
|
| 76 |
AST |
A measurement of the aspartate aminotransferase in a biological specimen. |
IU.L-1 |
|
|
| 77 |
BUN |
A measurement of the urea nitrogen in a blood specimen. |
ug.mL-1 |
|
|
| 78 |
CO2 |
A measurement of the carbon dioxide gas in a biological specimen. |
nM |
|
|
| 79 |
EOS |
A measurement of the eosinophils in a biological specimen. |
cells.uL-1 |
|
|
| 80 |
GGT |
A measurement of the gamma glutamyl transferase in a biological specimen. |
IU.L-1 |
|
|
| 81 |
HCT |
The percentage of a whole blood specimen that is composed of red blood cells (erythrocytes). |
% |
|
|
| 82 |
HGB |
A measurement of the hemoglobin in a biological specimen. |
ug.mL-1 |
|
|
| 83 |
LDH |
A measurement of the lactate dehydrogenase in a biological specimen. |
U.L-1 |
|
|
| 84 |
LDH |
A measurement of the lactate dehydrogenase in a biological specimen. |
IU.L-1 |
|
|
| 85 |
LYM |
A measurement of the lymphocytes in a biological specimen. |
cells.uL-1 |
|
|
| 86 |
MCH |
A quantitative measurement of the mean amount of hemoglobin per erythrocyte in a biological specimen. |
pg |
|
|
| 87 |
MCV |
A quantitative measurement of the mean volume of erythrocytes in a biological specimen. |
fL |
|
|
| 88 |
RBC |
A measurement of the total erythrocytes in a biological specimen. |
cells.uL-1 |
|
|
| 89 |
WBC |
A measurement of the leukocytes in a biological specimen. |
cells.uL-1 |
|
|
| 90 |
APTT |
A measurement of the length of time that it takes for clotting to occur when reagents are added to a plasma specimen. The test is partial due to the absence of tissue factor (Factor III) from the reaction mixture. |
s |
|
|
| 91 |
BASO |
A measurement of the basophils in a biological specimen. |
cells.uL-1 |
|
|
| 92 |
BILI |
A measurement of the total bilirubin in a biological specimen. |
ug.mL-1 |
|
|
| 93 |
CHOL |
A measurement of the cholesterol in a biological specimen. |
ug.mL-1 |
|
|
| 94 |
GLUC |
A measurement of the glucose in a biological specimen. |
ug.mL-1 |
|
|
| 95 |
MCHC |
A quantitative measurement of the mean amount of hemoglobin per erythrocytes in a specified volume of a biological specimen. |
% |
|
|
| 96 |
MCHC |
A quantitative measurement of the mean amount of hemoglobin per erythrocytes in a specified volume of a biological specimen. |
ug.mL-1 |
|
|
| 97 |
MONO |
A measurement of the monocytes in a biological specimen. |
cells.uL-1 |
|
|
| 98 |
PHOS |
A measurement of the phosphate in a biological specimen. |
ug.mL-1 |
|
|
| 99 |
PLAT |
A measurement of the platelets (non-nucleated thrombocytes) in a biological specimen. |
cells.uL-1 |
|
|
| 100 |
PROT |
A measurement of a group of complex organic macromolecules composed of one or more alpha-L-amino acid chains in a biological specimen. |
ug.mL-1 |
|
|
| 101 |
TRIG |
A measurement of the triglycerides in a biological specimen. |
ug.mL-1 |
|
|
| 102 |
CREAT |
A measurement of the creatinine in a biological specimen. |
ug.mL-1 |
|
|
| 103 |
EOSLE |
A relative measurement (ratio or percentage) of the eosinophils to leukocytes in a biological specimen. |
% |
|
|
| 104 |
LYMLE |
A relative measurement (ratio or percentage) of the lymphocytes to leukocytes in a biological specimen. |
% |
|
|
| 105 |
URATE |
A measurement of the urate in a biological specimen. |
ug.mL-1 |
|
|
| 106 |
BASOLE |
A relative measurement (ratio or percentage) of the basophils to leukocytes in a biological specimen. |
% |
|
|
| 107 |
BILDIR |
A measurement of the conjugated or water-soluble bilirubin in a biological specimen. |
ug.mL-1 |
|
|
| 108 |
LIPASE |
A measurement of the pancreatic lipase in a biological specimen. |
U.L-1 |
|
|
| 109 |
MONOLE |
A relative measurement (ratio or percentage) of the monocytes to leukocytes in a biological specimen. |
% |
|
|
| 110 |
NEUTLE |
A relative measurement (ratio or percentage) of the neutrophils to leukocytes in a biological specimen. |
% |
|
|
| 111 |
NEUTSG |
A measurement of the segmented neutrophils in a biological specimen. |
cells.uL-1 |
|
|
| 112 |
RBCNUC |
A measurement of the nucleated erythrocytes (large, immature nucleated erythrocytes) in a biological specimen. |
/100WBC |
|
|
| 113 |
SODIUM |
A measurement of the sodium in a biological specimen. |
mEq.L-1 |
|
|
| 114 |
TERMBW |
The weight of a subject at a specified end point. (NCI) |
g |
|
|
| 115 |
WEIGHT |
The vertical force exerted by a mass as a result of gravity. (NCI) |
g |
|
|
| 116 |
ALBGLOB |
The ratio of albumin to globulin in a biological specimen. |
- |
|
|
| 117 |
CALCIUM |
A measurement of the calcium in a biological specimen. |
ug.mL-1 |
|
|
| 118 |
FIBRINO |
A measurement of the fibrinogen in a biological specimen. |
ug.mL-1 |
|
|
| 119 |
PHOSLPD |
A measurement of the phospholipids in a biological specimen. |
ug.mL-1 |
|
|
| 120 |
RETIRBC |
A relative measurement (ratio or percentage) of reticulocytes to erythrocytes in a biological specimen. |
% |
|
|
| 121 |
CHLORIDE |
A measurement of the chloride in a biological specimen. |
mEq.L-1 |
|
|
| 122 |
POTASSIUM |
A measurement of the potassium in a biological specimen. |
mEq.L-1 |
|
|
| 124 |
AUC |
Area under the drug concentration time curve |
uM.hr |
0.001 |
10000 |
| 127 |
AUC |
Area under the drug concentration time curve |
ng.hr.mL-1 |
10 |
10000000 |
| 130 |
fAUC |
Area under the free drug concentration time curve |
uM.hr |
0.001 |
10000 |
| 134 |
fAUC |
Area under the free drug concentration time curve |
ng.hr.mL-1 |
10 |
10000000 |
| 135 |
CL |
Clearance |
uL.min-1.(10^6cells)-1 |
0.1 |
500 |
| 136 |
Compound recovery |
Recovery of a specific compound (e.g. parent or metabolite) in plasma, tissue or excreta, e.g. as absolute or qualitative measurement, percentage of dose recovered |
ng.eq.g-1 |
|
|
| 137 |
Radiolabel recovery |
Recovery of radioactivity in plasma, tissue or excreta after administration of radiolabelled compound, as absolute measurement or percentage of dose |
ng.eq.g-1 |
|
|
| 138 |
Compound recovery |
Recovery of a specific compound (e.g. parent or metabolite) in plasma, tissue or excreta, e.g. as absolute or qualitative measurement, percentage of dose recovered |
ng.eq.mL-1 |
|
|
| 139 |
Radiolabel recovery |
Recovery of radioactivity in plasma, tissue or excreta after administration of radiolabelled compound, as absolute measurement or percentage of dose |
ng.eq.mL-1 |
|
|
| 140 |
Compound recovery |
Recovery of a specific compound (e.g. parent or metabolite) in plasma, tissue or excreta, e.g. as absolute or qualitative measurement, or percentage of dose recovered |
% |
|
|
| 141 |
Radiolabel recovery |
Recovery of radioactivity in plasma, tissue or excreta after administration of radiolabelled compound, as absolute measurement or percentage of dose |
% |
|
|
| 142 |
AUC |
Area under the drug concentration time curve |
ng.hr.g-1 |
|
|
| 143 |
Cmax |
Maximum concentration |
ug.g-1 |
|
|
| 144 |
Log S |
Log of solubility |
- |
|
|
| 145 |
Kb |
Equilibrium binding constant |
nM |
0.01 |
100000 |
| 146 |
LogD |
Log(Distribution Coefficient) |
- |
-10 |
15 |
| 147 |
LogD7.4 |
Log(Distribution Coefficient) at pH 7.4 |
- |
-10 |
15 |
| 148 |
Delta Tm |
Change in melting temperature |
degrees C |
|
|
| 149 |
Fu |
Fraction of compound unbound |
- |
0 |
1 |
| 150 |
PPB |
Plasma protein binding as %bound |
% |
0 |
105 |
| 152 |
DOSE |
Amount of a substance administered |
mg.kg-1 |
|
|
| 153 |
TIME |
Point at which an experimental intervention is performed e.g., dosing of a substance, measuring a sample |
hr |
|
|
| 154 |
LogD5.0 |
Log(Distribution Coefficient) at pH 5.0 |
- |
-10 |
15 |
| 155 |
LogD6.5 |
Log(Distribution Coefficient) at pH 6.5 |
- |
-10 |
15 |
| 156 |
LogD5.5 |
Log(Distribution Coefficient) at pH 5.5 |
- |
-10 |
15 |
| 159 |
APDc |
Normalised action potential duration (APD) defined as: APD (ms) / cube root of Beat Interval (ms) |
- |
|
|
| 160 |
FPDc |
Normalised field potential duration (FPD) defined as: FPD (ms) / cube root of Beat Interval (ms) |
- |
|
|
| 161 |
Stability |
A measurement of the chemical or metabolic stability of the compound. |
% |
|
|